Clinical Report: Can Finerenone Alter Glomerular Disease Trajectory?
Overview
Finerenone demonstrated a slower decline in eGFR compared to placebo in patients with glomerular diseases. The treatment also significantly reduced urinary albumin-to-creatinine ratios in the immunoglobulin A nephropathy subgroup.
Background
Chronic kidney disease (CKD) is a major public health concern, particularly in patients with glomerular diseases. Effective management strategies are crucial to slow disease progression and improve patient outcomes. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has shown promise in managing CKD, particularly in diabetic populations, but its effects in nondiabetic glomerular diseases require further exploration.
Data Highlights
| Parameter | Finerenone | Placebo |
|---|---|---|
| eGFR slope (mL/min/1.73 m² per year) | -3.50 | -4.23 |
| Kidney failure or sustained eGFR decline (events per 100 patient-years) | 7.42 | 9.60 |
| Reduction in urinary albumin-to-creatinine ratio (12 months) | 47% | N/A |
Key Findings
- Finerenone reduced the eGFR decline by 0.73 mL/min/1.73 m² per year compared to placebo.
- In the immunoglobulin A nephropathy subgroup, finerenone reduced urinary albumin-to-creatinine ratio by 47%.
- Serious adverse events occurred in 20% of participants receiving finerenone.
- Finerenone was associated with a 1.22 mL/min/1.73 m² per year attenuation of chronic eGFR decline after 3 months.
- Subgroup analyses showed a treatment effect of 1.34 mL/min/1.73 m² per year in focal segmental glomerulosclerosis.
Clinical Implications
The findings suggest that finerenone may be a beneficial treatment option for patients with glomerular diseases, particularly in slowing eGFR decline and reducing proteinuria. Clinicians should consider finerenone as part of a comprehensive management strategy for these patients, while monitoring for potential adverse effects.
Conclusion
Finerenone shows promise in altering the trajectory of glomerular disease by slowing eGFR decline and reducing proteinuria. Further studies are warranted to confirm these findings and explore its long-term benefits.
Related Resources & Content
- JAMA Cardiology, 2023 -- Finerenone, New-Onset Atrial Fibrillation, and Prognosis in HFpEF/HFmrEF
- Frontiers in Medicine, 2026 -- Stress Hyperglycemia Ratio (SHR) and Triglyceride-Glucose Index (TYG) Associated with Renal Response to Finerenone in Diabetic Kidney Disease: A Retrospective Cohort Study
- Clinical Research in Cardiology, 2015 -- Long-term renal function and perfusion alterations in patients with heart failure and reduced ejection fraction
- KDIGO 2024 CLINICAL PRACTICE GUIDELINE
- Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes - PMC
- conexiant — Risk Model Stratifies Heart Failure Outcomes
- KDIGO 2024 CKD Guidelines
- Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes - PMC
- Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
